IRIDEX Corporation (IRIX)
| Market Cap | 19.67M +19.2% |
| Revenue (ttm) | 52.58M +7.7% |
| Net Income | -3.28M |
| EPS | -0.19 |
| Shares Out | 17.41M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 63,556 |
| Open | 1.170 |
| Previous Close | 1.170 |
| Day's Range | 1.130 - 1.185 |
| 52-Week Range | 0.869 - 1.648 |
| Beta | 0.66 |
| Analysts | Strong Buy |
| Price Target | 2.75 (+143.36%) |
| Earnings Date | May 19, 2026 |
About IRIX
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retino... [Read more]
Financial Performance
In fiscal year 2025, IRIDEX's revenue was $52.68 million, an increase of 8.23% compared to the previous year's $48.67 million. Losses were -$4.44 million, -50.20% less than in 2024.
Financial StatementsAnalyst Summary
According to one analyst, the rating for IRIX stock is "Strong Buy" and the 12-month stock price target is $2.75.
News
IRIDEX Transcript: Planet MicroCap Las Vegas 2026
The event highlighted strong financial turnaround, operational efficiencies, and a focus on expanding recurring revenue from glaucoma probes. Clinical data and regulatory changes are driving broader adoption, while international growth is expected as new products gain approval.
Iridex to Present at the Planet MicroCap Las Vegas 2026 Conference
MOUNTAIN VIEW, Calif., June 09, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and pro...
IRIDEX Slides: Investor presentation
IRIDEX has posted slides in relation to its latest quarterly earnings report, which was published on June 1, 2026.
IRIDEX Transcript: Lytham Partners Spring 2026 Investor Conference
IRIDEX highlighted its transformation in laser-based eye care, strong global presence, and broad product portfolio for retina and glaucoma. Achieving profitability in Q4 2025, the company emphasized clinical advantages of MicroPulse technology and operational efficiencies driving sustained growth.
IRIDEX Earnings Call Transcript: Q1 2026
Q1 2026 revenue was $11.8M, flat year-over-year, with strong G6 probe growth offsetting weaker Retina sales due to international headwinds. Cost reduction and manufacturing initiatives are on track, and 2026 guidance of $51–$53M revenue and positive cash flow is reaffirmed.
IRIDEX Earnings release: Q1 2026
IRIDEX released its Q1 2026 earnings on May 19, 2026, summarizing the period's financial results.
IRIDEX Quarterly report: Q1 2026
IRIDEX has published its Q1 2026 quarterly earnings report on May 19, 2026.
Iridex Reports First Quarter 2026 Financial Results
MOUNTAIN VIEW, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and proc...
Iridex to Report First Quarter 2026 Financial Results on May 19, 2026
MOUNTAIN VIEW, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and acce...
IRIDEX Proxy statement: Proxy filing
IRIDEX filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
IRIDEX Proxy statement: Proxy filing
IRIDEX filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Iridex announces new partnership with EyeProGPO
Iridex (IRIX) announced a new partnership with EyeProGPO. Through this partnership, the 1,800 plus EyeProGPO members can receive preferred pricing on the Iridex Pascal laser platform, IQ 532 and IQ…
Iridex Announces New Partnership with EyeProGPO to Expand Member Access to Retina Laser Technology
MOUNTAIN VIEW, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and ac...
Iridex price target lowered to $2.75 from $3 at Alliance Global
Alliance Global lowered the firm’s price target on Iridex (IRIX) to $2.75 from $3 and keeps a Buy rating on the shares. The firm views the company’s Q4 report as…
IRIDEX Earnings Call Transcript: Q4 2025
Revenue grew 8% to $52.7M in 2025 with strong Q4 growth and positive adjusted EBITDA. Cost reductions and operational streamlining led to positive cash flow, while 2026 guidance projects 1–5% growth excluding Middle East sales.
IRIDEX Annual report: Q4 2025
IRIDEX has published its Q4 2025 annual report on March 26, 2026.
IRIDEX Earnings release: Q4 2025
IRIDEX released its Q4 2025 earnings on March 26, 2026, summarizing the period's financial results.
Iridex Reports Fourth Quarter and Full Year 2025 Financial Results
Strong Q4 and Full Year 2025 Revenue Performance Underpinned by Continued Operational Efficiencies Strong Q4 and Full Year 2025 Revenue Performance Underpinned by Continued Operational Efficiencies
Iridex to Report Fourth Quarter and Full Year 2025 Financial Results on March 26, 2026
MOUNTAIN VIEW, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and pr...
Iridex initiated with a Buy at Alliance Global
Alliance Global initiated coverage of Iridex (IRIX) with a Buy rating and $3 price target The ophthalmic medical technology company’s key growth drivers include the Cyclo G6 laser system for…
Iridex announces plans to relocate headquarters
Iridex (IRIX) announced its intent to relocate the Company’s headquarters from Mountain View, California to San Jose, California. On January 26, 2026, the Company signed a non-binding letter of intent...
Iridex Announces Plans to Relocate Headquarters
MOUNTAIN VIEW, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and pro...
Iridex reports preliminary Q4 revenue $14.6M-$14.8M
Total revenue is expected to be between $14.6 million and $14.8 million compared to $12.7 million in the prior year quarter, representing year-over-year growth between 15% and 17%. “In 2025,…
Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2025
MOUNTAIN VIEW, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and pro...
IRIDEX Transcript: Sidoti's Year End Virtual Investor Conference
The company is leveraging innovative laser technologies and strong clinical data to expand in both retina and glaucoma markets, with a focus on operational efficiency and margin improvement. Recent cost reductions, product launches, and a robust replacement cycle support a positive financial outlook.